+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 2Years +
All Genders
ID07637734

Evaluation of YCANTH VP-102TO-208 Versus Placebo for Treating Common Warts in Children and Adults

Led by Verrica Pharmaceuticals Inc. · Updated on 2026-09-03

300

Participants Needed

20

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

The trial investigates the use of YCANTH VP-102TO-208 for treating common warts in children and adults aged 2 years and older. This Phase 3 study is double-blind, randomized, and vehicle-controlled, aiming to evaluate the safety and effectiveness of YCANTH compared to a placebo vehicle. Common warts caused by the human papilloma virus HPV are the focus, excluding certain wart types and locations. Participants receive topical applications of either YCANTH or a placebo vehicle every 21 days for up to four treatments during a 75-day period. The treated warts are covered with occlusive tape overnight following the application. Treatment may be delayed if temporary local skin reactions occur, and participants must attend all scheduled treatment and follow-up visits regardless of wart clearance. In Japan, participants completing this study may join a long-term follow-up study for up to 54 weeks to monitor safety and efficacy. Participants undergo wart measurements, dermatologic exams, and evaluation of treatment responses during visits. Follow-up includes in-person visits and phone calls to assess clearance and monitor adverse events. Researchers measure the proportion of participants achieving complete wart clearance at Day 84 and monitor safety through adverse event reporting and skin reaction assessments. The total participant involvement spans screening, treatment, and follow-up periods totaling several months.

CONDITIONS

Brief Title

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

Research Team

P

Project Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here